Simon is the CEO of MonTa Biosciences since establishment in 2015 and has led the company through several financing rounds and secured licensing on the companys current assets. Simon has a background as R&D manager in the biotech industry and is experienced in innovation, management, oncology, immunology, drug delivery, patenting and licensing. See more about Dr Jensen here.

Morten is the CDO of MonTa Biosciences. Prior to joining MonTa Morten has held management positions in the biotech industry and had led several drug development programmes from tox/safety through clinical phases.
Morten has a background in managing drug development activities in the biotech industry and is experienced in CMC, clinical trials, regulatory interactions and vendor management. See more about Mr Petersen here.

Steven is an seasoned healthcare and biotech professional with extensive knowledge of research and development, medical and regulatory affairs. His background encompasses senior management and hands-on experience from pharmaceutical, biopharmaceutical, biotechnology and diagnostic industries in Europe and the United States. Previous positions include senior assignments at: Novo Nordisk, Dade Behring, Zealand Pharma, BioInvent, Hansa Medical. See more about Mr Glazer here.

Thomas is a serial entrepreneur and has started a number of biotech companies in Denmark and the US. Thomas is Key Opinion Leader in the drug delivery field and Department Head of DTU Health and group leader of the Colloids and Biological Interfaces group at DTU Helth. Thomas is expert in biomaterial engineering for drug delivery and imaging applications. Thomas has a strong academic experience in the fields of organic chemistry, biophysics, nanotechnology and nanomedicine, drug delivery and cancer biology, and holds a track record of more than 70 research or review articles and patent applications.  

Dr. Birk is an experienced business accelerator and investor and part of the Accelerace Management team. Dr Birk has a background from management positions in the biotech industry as VP in EpiTherapeutics and Pharmexa, and CSO in ACE BioSciences. Dr Birk has a strong experience in the field of vaccines and immunotherapy, enabling him to strengthen MonTa Biosciences in both business and R&D. See more about Dr Birk here.

Dr. Boel is VP of the Danish branch of DragonFly Therapeutics and BoD member at Paratech A/S, former CVP and head of Biotechnology at Novo Nordisk A/S and former CTO at Symphogen A/S. He was centrally involved in building the inflammation and oncology portfolio at Novo Nordisk A/S from 2002 to 2013. Dr. Boel has held key strategic, consulting and advisory positions in several biotech companies with a focus on immunotherapy, making Dr. Boel a well-respected expert in R&D, business development and strategic aspects. See more about Dr Boel here.

Sven Madsen is CFO in Consolidated Holdings A/S and has a background as an auditor in a number of auditing firms. Sven Madsen has been working with corporate reporting, financing, and corporate management in Codan Insurance, FLS Industries, SystemForum, Atea and Consolidated Holdings. His special competencies are financial accounting, economic and financial trouble shooting and mergers and acquisitions, and is board members in a number of companies. Sven Madsen also holds a Graduate Diploma in Financial and Management Accounting and an MSc in Business Economics and Auditing. See more about Mr Madsen here.

Lone Schøtt Kunøe is CEO of Consolidated Holdings A/S and has a master of science in Economics. She has a background in the Danish central bank and in the predecessor of the European Central Bank before she got into management consulting and recruitment at the consultancy company Mercuri Urval.  She has been with Consolidated Holdings for almost 20 years – first as CFO and later as CEO mostly occupied with M&A as well as being chairman or board member of a number of companies – all part of the Consolidated Holdings’ portfolio of companies.